SAB4200783

Sigma-Aldrich

Anti-Human IgG2 antibody, Mouse monoclonal

clone HP-6014, purified from hybridoma cell culture

Synonym(s):
Anti-Human immunoglobulin G2
NACRES:
NA.46

Quality Level

biological source

mouse

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

HP-6014, monoclonal

form

buffered aqueous solution

species reactivity

human

concentration

~1.0 mg/mL

application(s)

immunofluorescence: suitable
indirect ELISA: 0.07-0.15 μg/mL using 1 μg/mL Human IgG2 myeloma for coating

isotype

IgG1

shipped in

dry ice

storage temp.

−20°C

General description

Anti-Human IgG2 antibody, Mouse monoclonal (mouse IgG1 isotype) is derived from the HP-6014 hybridoma, produced by the fusion of mouse myeloma cells and splenocytes from a mouse immunized with purified human IgG2 myeloma proteins covalently coupled to polyaminostyrene (PAS) microbeads. Human IgG consist of four subclasses (1-4) that can be recognized by antigenic differences in their heavy chains. They constitute approximately 65, 30, 5, and 4% of the total IgG, respectively.

Immunogen

Purified human IgG2 myeloma protein

Application

Anti-Human IgG2 antibody, Mouse monoclonal may be used in immunological techniques, including enzyme linked immunosorbent assay (ELISA), immunofluorescence, hemagglutination (HA) and hemagglutination inhibition.

Biochem/physiol Actions

Lipopolysaccharides stimulate an IgG2 response in peripheral blood leukocytes (PBL) and an IgG1 response in the spleen. Only IgG1 and IgG3 are capable of adherence to mononuclear phagocytes while IgG2 and IgG4 autoantibodies are much less efficient. The amount of the different IgG subclasses present in the blood shows variation with age. For example, IgG1 and IgG3 reach normal adult levels by 5-7 years of age while IgG2 and IgG4 levels raise more slowly, reaching adult levels at about 10 years of age. Serum IgG subclass deficiencies have been recorded for different patient groups. For example, IgG2 and IgG4 deficiency is found in patients of ataxia telangiectasia. Low IgG2 levels were found in patients with Systemic lupus erythematosus (SLE) and juvenile diabetes mellitus.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

U Kaur et al.
Scandinavian journal of immunology, 60(5), 524-528 (2004-11-16)
To demonstrate the dynamics of specific antibody isotypes against Entamoeba histolytica Gal/GalNAc adhesin and its correlation, if any, with the development of immunity, we evaluated subjects suffering from a spectrum of amoebic infections ranging from amoebic liver abscess (ALA) to...
Immunodeficiency and infections in ataxia-telangiectasia
Nowak-Wegrzyn A, et al.
The Journal of Pediatrics, 144(4), 505-511 (2004)
V A Oxelius et al.
Clinical and experimental immunology, 99(2), 211-215 (1995-02-01)
IgA deficiency (IgAD) is the most common immunodeficiency, characterized by an arrest in B cell differentiation. It has a sporadic occurrence or variable inheritance pattern, and is also linked to the HLA genes. IgA deficiency is sometimes associated with IgG...
Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy
Scott-Taylor TH, et al.
Immunity, inflammation and disease, 6, 13-33 (2018)
Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood
Blanco E, et al.
The Journal of Allergy and Clinical Immunology, 141(6), 2208-2219 (2018)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.